EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL

Authors :: G. Garcia-Manero
U. Platzbecker
V. Santini
A. Zeidan
P. Fenaux
R. Komrokji
J. Shortt
D. Valcarcel
A. Jonasova
S. Dimicoli-Salazar
I.S. Tiong
C.-C. Lin
J. Li
J. Zhang
A.C. Giuseppi
S. Kreitz
V. Pozharskaya
K. Keeperman
S. Rose
T. Prebet
A. Degulys
S. Paolini
T. Cluzeau
M. Della Porta
Source :: Leukemia Research Reports, Vol 21, Iss , Pp 100447- (2024)
Publication Year :: 2024
Publisher :: Elsevier, 2024.
Abstract: Introduction: We report the full analysis of the COMMANDS trial assessing efficacy and safety of luspatercept versus epoetin alfa (EA) in ESA-naive patients with LR-MDS. Methods: 363 patients (aged ≥18 y, with transfusion-dependent LR-MDS, serum erythropoietin

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools